(HLN) Haleon - Ratings and Ratios
Toothpaste, Vitamins, Pain-Relief, Antacids, Cold-Remedies
HLN EPS (Earnings per Share)
HLN Revenue
Description: HLN Haleon September 29, 2025
Haleon plc (NYSE:HLN) is a global consumer-health company that designs, manufactures, and markets a portfolio of over-the-counter (OTC) products across North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Its core categories include oral-care (Sensodyne, Polident, Parodontax, Aquafresh, Biotene), vitamins and supplements (Centrum, Emergen-C, Caltrate), respiratory relief (Otrivine, Theraflu, Flonase), pain and anti-inflammatory agents (Voltaren, Panadol, Advil), and digestive health (TUMS, ENO, Fenistil).
Formed from the spin-off of GSK’s consumer-health business in 2022, Haleon inherited legacy brands and a historic lineage dating back to 1715, with its headquarters in Weybridge, United Kingdom. The company trades as a common stock under the ticker HLN and is classified in the GICS sub-industry “Biotechnology,” reflecting its focus on health-related consumer products rather than prescription drugs.
According to the most recent FY 2023 filing, Haleon reported net sales of approximately $5.7 billion, a 3.2 % year-over-year increase driven largely by strong demand for its oral-care and vitamin lines in the United States and Europe. Adjusted earnings per share rose to $2.10, and the firm maintained a dividend yield near 2.5 %, underscoring its commitment to returning cash to shareholders while funding incremental R&D and marketing spend.
Key macro drivers for Haleon include the aging global population, which expands the market for vitamins, joint-pain relief, and digestive health products, and a post-pandemic shift toward self-managed health care that is boosting OTC sales at a compound annual growth rate of roughly 4 % worldwide. Additionally, inflationary pressure on consumer discretionary spending creates pricing discipline, but Haleon’s premium-brand positioning and cost-efficiency initiatives have helped preserve operating margins above the sector average.
For a deeper, data-rich assessment of Haleon’s valuation metrics and competitive positioning, you may find it worthwhile to explore the analyst tools available on ValueRay.
HLN Stock Overview
| Market Cap in USD | 40,587m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-07-22 |
HLN Stock Ratings
| Growth Rating | 50.6% |
| Fundamental | 52.8% |
| Dividend Rating | 53.4% |
| Return 12m vs S&P 500 | -18.1% |
| Analyst Rating | 4.0 of 5 |
HLN Dividends
| Dividend Yield 12m | 1.88% |
| Yield on Cost 5y | 2.46% |
| Annual Growth 5y | 50.96% |
| Payout Consistency | 100.0% |
| Payout Ratio | 47.6% |
HLN Growth Ratios
| Growth Correlation 3m | -52.3% |
| Growth Correlation 12m | 7.1% |
| Growth Correlation 5y | 88.5% |
| CAGR 5y | 17.26% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.75 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.67 |
| Sharpe Ratio 12m | 0.95 |
| Alpha | -11.40 |
| Beta | 0.229 |
| Volatility | 20.53% |
| Current Volume | 5335.8k |
| Average Volume 20d | 8589.8k |
| Stop Loss | 9 (-3.9%) |
| Signal | 0.39 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.52b TTM) > 0 and > 6% of Revenue (6% = 661.1m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -2.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5.63% (prev -8.12%; Δ 2.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 3.33b > Net Income 1.52b (YES >=105%, WARN >=100%) |
| Net Debt (7.78b) to EBITDA (2.66b) ratio: 2.93 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.53b) change vs 12m ago -1.61% (target <= -2.0% for YES) |
| Gross Margin 62.94% (prev 60.68%; Δ 2.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.79% (prev 33.71%; Δ 0.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.86 (EBITDA TTM 2.66b / Interest Expense TTM 201.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.21
| (A) -0.02 = (Total Current Assets 4.14b - Total Current Liabilities 4.76b) / Total Assets 31.83b |
| (B) 0.86 = Retained Earnings (Balance) 27.27b / Total Assets 31.83b |
| warn (B) unusual magnitude: 0.86 — check mapping/units |
| (C) 0.07 = EBIT TTM 2.38b / Avg Total Assets 32.61b |
| (D) 1.01 = Book Value of Equity 15.94b / Total Liabilities 15.83b |
| Total Rating: 4.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 52.79
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 2.44% = 1.22 |
| 3. FCF Margin 8.45% = 2.11 |
| 4. Debt/Equity 0.53 = 2.36 |
| 5. Debt/Ebitda 2.93 = -1.66 |
| 6. ROIC - WACC (= 1.57)% = 1.96 |
| 7. RoE 9.40% = 0.78 |
| 8. Rev. Trend -55.27% = -4.15 |
| 9. EPS Trend -6.78% = -0.34 |
What is the price of HLN shares?
Over the past week, the price has changed by +1.85%, over one month by +4.93%, over three months by -3.31% and over the past year by -3.61%.
Is Haleon a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HLN is around 9.26 USD . This means that HLN is currently overvalued and has a potential downside of -1.17%.
Is HLN a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.6 | 24.2% |
| Analysts Target Price | 11.6 | 24.2% |
| ValueRay Target Price | 10.1 | 7.3% |
HLN Fundamental Data Overview October 13, 2025
P/E Trailing = 20.0
P/E Forward = 16.5289
P/S = 3.6834
P/B = 1.8455
P/EG = 2.664
Beta = 0.229
Revenue TTM = 11.02b GBP
EBIT TTM = 2.38b GBP
EBITDA TTM = 2.66b GBP
Long Term Debt = 7.58b GBP (from longTermDebt, last quarter)
Short Term Debt = 813.0m GBP (from shortTermDebt, last quarter)
Debt = 8.45b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.78b GBP (from netDebt column, last quarter)
Enterprise Value = 38.13b GBP (30.35b + Debt 8.45b - CCE 676.0m)
Interest Coverage Ratio = 11.86 (Ebit TTM 2.38b / Interest Expense TTM 201.0m)
FCF Yield = 2.44% (FCF TTM 931.0m / Enterprise Value 38.13b)
FCF Margin = 8.45% (FCF TTM 931.0m / Revenue TTM 11.02b)
Net Margin = 13.81% (Net Income TTM 1.52b / Revenue TTM 11.02b)
Gross Margin = 62.94% ((Revenue TTM 11.02b - Cost of Revenue TTM 4.08b) / Revenue TTM)
Gross Margin QoQ = 64.51% (prev 64.51%)
Tobins Q-Ratio = 1.20 (Enterprise Value 38.13b / Total Assets 31.83b)
Interest Expense / Debt = 1.31% (Interest Expense 111.0m / Debt 8.45b)
Taxrate = 24.37% (131.0m / 537.5m)
NOPAT = 1.80b (EBIT 2.38b * (1 - 24.37%))
Current Ratio = 0.87 (Total Current Assets 4.14b / Total Current Liabilities 4.76b)
Debt / Equity = 0.53 (Debt 8.45b / totalStockholderEquity, last quarter 15.94b)
Debt / EBITDA = 2.93 (Net Debt 7.78b / EBITDA 2.66b)
Debt / FCF = 8.35 (Net Debt 7.78b / FCF TTM 931.0m)
Total Stockholder Equity = 16.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.78% (Net Income 1.52b / Total Assets 31.83b)
RoE = 9.40% (Net Income TTM 1.52b / Total Stockholder Equity 16.19b)
RoCE = 10.03% (EBIT 2.38b / Capital Employed (Equity 16.19b + L.T.Debt 7.58b))
RoIC = 7.15% (NOPAT 1.80b / Invested Capital 25.20b)
WACC = 5.58% (E(30.35b)/V(38.80b) * Re(6.86%) + D(8.45b)/V(38.80b) * Rd(1.31%) * (1-Tc(0.24)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.35%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈1.26b ; Y1≈830.0m ; Y5≈379.6m
Fair Price DCF = 1.68 (DCF Value 7.46b / Shares Outstanding 4.45b; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -6.78 | EPS CAGR: -58.68% | SUE: -0.23 | # QB: 0
Revenue Correlation: -55.27 | Revenue CAGR: -1.94% | SUE: 0.10 | # QB: 0
Additional Sources for HLN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle